Last reviewed · How we verify
NCT04068766: PALM
Efficacy of Paracervical Block in Laparoscopic Myomectomy: a Randomized Controlled Trial (PALM)
NA trial testing Paracervical block in Uterine Fibroid in 62 participants. Status unknown.
1 August 2020
Quick facts
| Lead sponsor | Kangbuk Samsung Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 62 |
| Start date | 23 August 2019 |
| Primary completion | 1 August 2020 |
| Estimated completion | 1 August 2020 |
| Sites | 2 locations across South Korea |
Drugs / interventions tested
- Paracervical block — full drug profile →
- 5% bupivacaine
- Normal saline
Conditions studied
- Uterine Fibroid — all drugs for Uterine Fibroid →
Sponsor
Kangbuk Samsung Hospital
Who can join
Adults 18 to 60, female only, with Uterine Fibroid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It remains controversial whether paracervical block should be performed as a powerful strategy for pain relief in laparoscopic myomectomy (LM), because convincing conclusions are difficult to draw because of the heterogeneous and contradictory nature of the literature. Therefore, the aim of this study was to evaluate the efficacy of paracervical blocks using with 0.5% bupivacaine prior to LM for benign gynecologic conditions on postoperative pain relief.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04068766
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Paracervical block
Trials testing the same drug.
- NCT03792009 — Paracervical Block in Laparoscopic Hysterectomy · NA · unknown
Other recruiting trials for Uterine Fibroid
Currently open trials in the same condition.
- NCT07173127 — The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemos · NA · recruiting
- NCT06705075 — Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE · Phase 2 · recruiting
- NCT06244251 — Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids · NA · active not recruiting
- NCT05386615 — Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids · recruiting
Other Kangbuk Samsung Hospital trials
Trials by the same sponsor.
- NCT07396961 — Consistency of ASIS Line vs. Tuffier's Line for Lumbar Level Identification · not yet recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT06773585 — Investigations of Factors Associated With Treatment Response and Prognosis in Anxiety Disorders · not yet recruiting
- NCT06130137 — Gut Microbiome in People Living With HIV and HBV · not yet recruiting
- NCT05538741 — Hypotension After Anesthetic Induction with Remimazolam in Elderly · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04068766 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kangbuk Samsung Hospital
- Last refreshed: 28 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04068766.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing